| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2017161144 |
| Title |
Carbonic Anhydrase Ix Inhibitor Conjugates and Uses Thereof. |
| Abstract |
The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in imaging methods and cancer therapy. |
| Applicant(s) |
Endocyte, Inc |
| Patent ID |
WO2009089383 |
| Title |
Inhibitors of Carbonic Anhydrase Ix. |
| Abstract |
Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which Ls capable of binding the active catalytic site of CA- IX, and a radionuclide adapted for radioimaging and/or radiotherapy:. |
| Applicant(s) |
Molecular Insight Pharmaceuticals, Inc |
| Patent ID |
WO2017161170 |
| Title |
Carbonic Anhydrase Ix Targeting Agents and Methods. |
| Abstract |
The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in SPECT imaging methods. |
| Applicant(s) |
Purdue Research Foundation |
| Patent ID |
WO2016100980 |
| Title |
Carbonic Anhydrase Ix Specific Chimeric Antigen Receptors and Methods of Use Thereof. |
| Abstract |
The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma. |
| Applicant(s) |
Dana-Farber Cancer Institute, Inc |
| Patent ID |
WO2012087115 |
| Title |
Cancer Targeting Using Carbonic Anhydrase Isoform Ix Inhibitors. |
| Abstract |
The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art. The present invention relates to novel nitroimidazole derivates represented by formula (1). |
| Applicant(s) |
Stichting Maastricht Radiation Oncology "Maastro - Clinic" |
| Patent ID |
WO2011139375 |
| Title |
Antibodies Directed Against Carbonic Anhydrase Ix and Methods and Uses Thereof. |
| Abstract |
Specific binding members, particularly antibodies and fragments thereof, which bind to Carbonic Anhydrase IX (CAIX) are provided, particularly including recognizing both human and mouse CAIX and blocking or inhibiting CAIX activity. These antibodies are useful in the diagnosis and treatment of cancer and in conditions associated with hypoxia and/or elevated CAIX activity. The anti-CAIX antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anticancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies MSC 1 through MSC 12 whose sequences are provided herein. |
| Applicant(s) |
Univ Oxford |
| Patent ID |
WO2007065027 |
| Title |
Carbonic Anhydrase Ix (G250) Antibodies and Methods of Use Thereof. |
| Abstract |
The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby. |
| Applicant(s) |
Dana-Farber Cancer Institute, Inc |
| Patent ID |
WO087115 |
| Title |
Cancer Targeting Using Carbonic Anhydrase Isoform Ix Inhibitors. |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US2017035892 |
| Title |
Small Molecule Drug Conjugates. |
| Representative Drug(s) |
D06LLY |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0W9VU
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
US2016009664 |
| Title |
Metal Complexes of Poly(Carboxyl)Amine-Containing Ligands Having An Affinity for Carbonic Anhydrase Ix. |
| Patent ID |
US2008138291 |
| Title |
Scozzafava A Sulfonamide Derivatives Having Carbonic Anhydrase Inhibiting Activity and Their Use As Therapeutic and Diagnostic Agents. |
| Representative Drug(s) |
D0UK9U |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US2008095707 |
| Title |
Ca Ix-Specific Inhibitors. |
| Representative Drug(s) |
D01YQE |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US2016015661 |
| Title |
Assembly Comprising An Absorber of Near Infrared (Nir) Light Covalently Linked To An Inhibitor of Carbonic Anhydrase. |
| Patent ID |
US2013336923 |
| Title |
Carbonic Anhydrase Ix (G250) Antibodies and Methods of Use Thereof. |
| European Patent Office (EPO) |
| Patent ID |
EP2468734 |
| Title |
Development of Molecular Imaging Probes for Carbonic Anhydrase-Ix Using Click Chemistry. |
| China National Intellectual Property Administration (CNIPA) |
| Patent ID |
CN102702109 |
| Title |
Benzenesulfonamide Compound and Application Thereof. |
| Abstract |
The invention relates to a benzenesulfonamide compound and application thereof. The benzenesulfonamide compound is a compound shown as a formula I or pharmaceutically acceptable salt thereof and can be used as a carbonic anhydrase IX inhibitor. In the formula I, R1 to R10 are independently selected from hydrogen, C1 to C6 straight-chain or branched-chain alkyl, C1 to C6 straight-chain or branched-chain alkoxy, amino and halogen, and halogenated straight-chain or branched-chain C1 to C6 alkyl or sulfamide, at least one of R1 to R10 is the sulfamide, X is NH, O or S, and n is 0 or 1. |
| Applicant(s) |
East China University of Science and Technology |
| Representative Drug(s) |
D08RPE |
Drug Info
|
N.A. |
[1] |
| Patent ID |
CN106278963 |
| Title |
Sulfonamides Compound of Target Carbonic Anhydrase Ix and Intermediate As Well As Preparation and Application Thereof. |
| Intellectual Property Office of Australia (IP Australia) |
| Patent ID |
AU2012211499 |
| Title |
Ca Ix-Specific Inhibitors. |
| Representative Drug(s) |
D01YQE |
Drug Info
|
N.A. |
[1] |
